Back to top
more

Sanofi (SNY)

(Delayed Data from NSDQ)

$53.10 USD

53.10
4,522,270

+1.90 (3.71%)

Updated Jul 25, 2024 04:00 PM ET

After-Market: $53.09 -0.01 (-0.02%) 5:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 20% (201 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

AstraZeneca's Forxiga Gets EC Approval for Type-I Diabetes

by Zacks Equity Research

AstraZeneca's (AZN) diabetes drug gets approval in Europe for type-1 diabetes as an adjunct to insulin in patients with a BMI greater or equal to 27 kg/m2.

Biogen Stock Crashes on Termination of Alzheimer's Studies

by Zacks Equity Research

Biogen (BIIB) and its Japanese partner, Eisai discontinue two late-stage studies evaluating aducanumab, in patients with Alzheimer's disease.

Emergent Begins Phase III Study on Anthrax Vaccine AV7909

by Zacks Equity Research

Emergent (EBS) kicks off a late-stage study on its investigational anthrax vaccine AV7909.

Regeneron, Sanofi Get EC Nod for Label Expansion of Praluent

by Zacks Equity Research

Regeneron (REGN) and partner Sanofi receives approval in Europe for the label expansion of Praluent to reduce cardiovascular (CV) risk in adults with established atherosclerotic CV disease.

Lexicon Pharma Initiates Dosing in Biliary Tract Cancer Study

by Zacks Equity Research

Lexicon Pharma (LXRX) commences dosing of first patient in phase IIa study evaluating its marketed drug, Xermelo, in biliary tract cancer.

Biotech Stock Roundup: REGN Gets FDA Nod for Dupixent & Other Pipeline News

by Zacks Equity Research

Key highlights of the past week are regulatory and pipeline developments.

Should Value Investors Consider Sanofi (SNY) Stock Now?

by Zacks Equity Research

Let's see if Sanofi (SNY) stock is a good choice for value-oriented investors right now from multiple angles.

Regeneron/Sanofi's Dupixent Gets FDA Nod for Label Expansion

by Zacks Equity Research

The FDA approves a label expansion of Regeneron's (REGN) asthma drug, Dupixent for moderate-to-severe atopic dermatitis in adolescents.

Sanofi's Dupixent Gets FDA Priority Status for Nasal Polyps

by Zacks Equity Research

Sanofi (SNY) and partner Regeneron's (REGN) Dupixent gets FDA's priority review status for inadequately controlled severe chronic rhinosinusitis with nasal polyps.

Roche's (RHHBY) sNDA for Flu Candidate Accepted by the FDA

by Zacks Equity Research

The FDA accepts Roche's (RHHBY) sNDA for Xofluza to treat influenza in people at high risk of complications.

Mark Vickery headshot

Top Stock Reports for Salesforce, Booking Holdings & VMware

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including salesforce (CRM), Booking Holdings (BKNG) and VMware (VMW).

Lilly to Bring Half-Priced Version of Popular Humalog Insulin

by Zacks Equity Research

Eli Lilly (LLY) plans to launch a cheaper version of its popular insulin, Humalog amid increasing pressure to lower drug costs.

What's in the Cards for Novavax (NVAX) This Earnings Season?

by Zacks Equity Research

Novavax (NVAX) is expected to provide updates on its lead vaccine candidate, Resvax when it reports fourth-quarter 2018 results.

Regeneron-Sanofi Get CHMP Nod for Dupixent Label Expansion

by Zacks Equity Research

The CHMP gives a positive opinion for the label expansion of Regeneron (REGN) and Sanofi's Dupixent for the treatment of asthma in Europe.

Pharma Stock Roundup: Roche to Buy ONCE, Lawmakers Grill CEOs Over High Drug Prices

by Zacks Equity Research

Roche (RHHBY) to buy Spark Therapeutics for $4.8 billion. Executives of big pharma companies face senators' questions over high drug prices.

Sanofi/Regeneron Disagree With Jury Verdict in Amgen's Favor

by Zacks Equity Research

Sanofi (SNY) and partner Regeneron (REGN) disagree with a jury verdict in favor of Amgen upholding the validity of two patents related to Repatha.

Emergent (EBS) Q4 Earnings, Revenues Surpass Estimates

by Zacks Equity Research

Emergent (EBS) rides high on both earnings and a revenue beat in Q4.

BioMarin (BMRN) Q4 Earnings & Sales Miss, Shares Decline

by Zacks Equity Research

BioMarin (BMRN) misses estimates for earnings and revenues in the fourth quarter. Shares decline in after-hours trading.

Ascendis Pharma Files IND for Hypoparathyroidism Candidate

by Zacks Equity Research

Ascendis Pharma (ASND) submits regulatory application to initiate a phase II study in the United States on its hypoparathyroidism therapy candidate, TransCon PTH.

Sanofi/Regeneron Cut Price of PCSK9 Inhibitor Praluent by 60%

by Zacks Equity Research

Sanofi (SNY) and Regeneron (REGN) announce a 60% cut in the U.S. list price of their cholesterol lowering drug, Praluent to improve access and affordability of the product.

    ImmunoGen (IMGN) Beats on Earnings & Sales in Q4, Shares Up

    by Zacks Equity Research

    ImmunoGen (IMGN) reports narrower-than-expected loss in Q4 and beats revenue estimates.

    Pharma Stock Roundup: Q4 Earnings at MRK, LLY, CHMP Nod for Several Drugs

    by Zacks Equity Research

    Merck (MRK) and Lilly (LLY) report Q4 results. CHMP gives nod to several drugs.

    Alnylam's (ALNY) Q4 Earnings and Revenues Beat Estimates

    by Zacks Equity Research

    Alnylam (ALNY) incurs wider year-over-year loss in the fourth quarter of 2018.

    Sanofi (SNY) Q4 Earnings Top, Genzyme Unit Drives Sales Growth

    by Zacks Equity Research

    Sanofi (SNY) beat estimates for earnings and missed the same for sales in the fourth quarter. The Specialty Care unit drove top-line growth.

    Regeneron Q4 Earnings & Sales Beat on Strong Dupixent, Eylea

    by Zacks Equity Research

    Regeneron's (REGN) earnings and sales surpass expectations in Q4 on solid Dupixent and Eylea sales.